Breaking News

Cobra Biologics Gains Approval for R&D Tax Credit

April 1, 2014

Offers R&D incentive for French companies

Cobra Biologics has been recognized by the French Ministry of Higher Education and Research (MESR) as an approved service provider for its antibody and recombinant protein services for the period 2013 to 2015. The approval allows French companies that outsource their R&D programs to Cobra’s centre of excellence, to receive a research tax credit.
 
The tax credit, which covers 30% of all R&D expenses up to €100 million, and 5% above this threshold, aims to encourage R&D efforts and enhance investments in France. 

Peter Coleman, chief executive officer of Cobra Biologics, said, “CIR is a real benefit to our French customers as it encourages them to invest in innovative drugs that are ultimately the driving force for the medicines of tomorrow.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.

  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.